SecBot SecBot
6-K ·Filed Jul 17, 2026

GSK

GSK plc
BEARISH
Impact 5/10
Horizonimmediate Processed4mo ago SEC0001654954-26-006705
Actionable Insight ▼ Bearish

The failed Phase III program removes a potential future revenue stream in RCC, a market with limited treatment options. For a $106.9B diversified pharma, this is a modest pipeline blow rather than a transformative event. Monitor the BALANCE trial in IBS-D/IBS-M for any remaining value in the camlipixant program, and watch for potential write-downs in the next quarterly filing. The stock may see a small negative reaction as the market prices out RCC peak sales expectations.

DirectionBearish
Confidencehigh
Horizonimmediate

Drug in focus

GSK drug pipeline →

camlipixant

▼ Bearish Named in this 6-K
Impact
Phase
Phase 3 (lead indication discontinued); Phase IIb ongoing in IBS-D/IBS-M
Time to market
Unknown in the surviving IBS indication (Phase IIb — still years from any possible filing); effectively zero path to market in its lead indication, refractory chronic cough, where development was discontinued in July 2026.
Next catalyst
None dated

What to watchThe defining binary has already passed and it was a miss: GSK booked a ~£1.9B impairment tied mostly to camlipixant that cut Q2 2026 operating profit by ~75% (to £481M), yet the stock is only a few percent off its 52-week high, confirming the drug is immaterial to a company this size. For GSK holders, watch the remaining Phase IIb IBS-D/IBS-M program for any signs of continued investment (or an eventual full exit from P2X3), and track competitors still chasing chronic cough (e.g., Trevi's Haduvio, Addex) as the class's commercial benchmark.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$51.76
T+0 close · Jul 17, 2026 · via day close
Latest settled
−9.35%
T+60 · $46.92
Vs SPY
−14.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 17 $51.76entry
  2. T+1 · 4mo ago −3.32%α −3.16% · $50.04
  3. T+5 · 4mo ago −1.97%α −1.28% · $50.74
  4. T+20 · 3mo ago −4.33%α −8.77% · $49.52
  5. T+60 · 5w ago −9.35%α −14.03% · $46.92
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK announced that its Phase III CALM-1 trial for camlipixant in refractory chronic cough met its primary endpoint (50mg BID at week 12), but the confirmatory CALM-2 trial failed to reach statistical significance on the same endpoint at week 24. The 25mg dose missed in both studies, and key secondary endpoints did not meet thresholds. Based on limited efficacy, GSK is discontinuing further development of camlipixant in RCC, though a Phase IIb trial in IBS-D/IBS-M continues. This is a clear pipeline setback for a mid-stage asset, though the financial impact is limited given GSK's scale ($106.9B market cap). The cross-filing context includes the 20-F annual report from March 2026, which provides baseline financial context but does not alter this filing's standalone interpretation. The cross-filing actuarial verdicts flag this as an amplifier combo (6k-activist-context + 6k-annual-context), but no activist context is present in the provided filings, so no override is applied.

Key Facts

  • CALM-1 met primary endpoint (camlipixant 50mg BID showed statistically significant reduction in 24-hour cough frequency vs placebo at week 12)
  • CALM-2 did not reach statistical significance on the same primary endpoint with 50mg BID at week 24
  • Camlipixant 25mg BID did not reach statistical significance in either study
  • Key secondary endpoints, including Chronic Cough Diary measure, did not meet target thresholds in either study
  • GSK has decided not to progress further development of camlipixant in RCC
  • Phase IIb BALANCE trial in IBS-D/IBS-M will continue

Financial Impact

Pipeline setback with no disclosed financial figures; R&D spend on camlipixant not quantified in filing

r&d pipeline value

Risk Factors

  • Complete discontinuation of camlipixant in RCC eliminates a potential growth driver in a high-unmet-need area
  • BALANCE trial in IBS-D/IBS-M may also fail, rendering the entire camlipixant program worthless
  • No disclosed financial impact or R&D impairment charge, leaving uncertainty about the scale of sunk costs

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
43% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (GSK), Batch item 10001654954-26-006705
Document: 0001654954-26-006705-index-headers.html0001654954-26-006705
Document: 0001654954-26-006705-index.html0001654954-26-006705
Document: 0001654954-26-006705.txt0001654954-26-006705
6-K Filing (GSK), Batch item 50001654954-26-006705
Document: 0001654954-26-006705-index-headers.html0001654954-26-006705
Document: 0001654954-26-006705-index.html0001654954-26-006705
Document: 0001654954-26-006705.txt0001654954-26-006705

US Market Status

Market Closed · Opens Wed (10h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 17, 2026